An Important Question in Ovarian Cancer Treatment Has Been Answered!

Ovarian cancer is the most common type of cancer in women after breast cancer. Among gynecological cancers in women, it is the type causing the most deaths. Cancer of the fallopian tubes is also treated using the same treatment strategy because of biological similarities. Because ovarian cancers spread through the peritoneum and lymph nodes, they often cause no signs early on and are diagnosed at a late stage. Almost 75% of patients are at stage 3C at diagnosis (peritoneal metastases of 2 cm or more, lymph node metastasis in the groin, tumor spread in the abdominal region called the retroperitoneum) or stage 4 (spread of disease outside the abdomen).
There are two important life-saving treatments for a patient diagnosed with ovarian cancer. The first is surgery to reduce tumor burden (cytoreductive surgery) and the other is chemotherapy. Chemotherapy has become a standard approach over the years, with the dose and drug type becoming clear beyond the need for debate. The aim of surgery should be to remove all visible tumors inside the abdomen, leaving only microscopic disease if possible, or to leave visible tumors smaller than 1 cm. It has been demonstrated that surgeries falling outside this aim provide minimal benefit to the patient and are the most important determinant of shortened survival.
The sequence of surgery and chemotherapy has been debated over the last 10 years. Should initial treatment begin with surgery, or should chemotherapy be given first, followed by surgery?
Results of well-designed comparative studies conducted during this period were analyzed, and a treatment guideline on this controversial issue was published in the October 2016 Journal of Clinical Oncology. According to this guideline, a patient newly diagnosed with ovarian cancer should undergo adequate imaging tests to determine the exact extent of disease.
These tests should include the Ca 125 level and tomography of the entire abdomen and chest, with PET Tomography and/or MRI performed additionally when necessary.
We Observe That a Considerable Number of Patients Undergo Surgery with Inadequate Imaging Examinations
After imaging, preoperative chemotherapy must be considered for patients with disease spread at stages 3C and 4. In this patient group (75% of newly diagnosed patients), chemotherapy before surgery significantly reduces undesirable consequences of surgical treatment and the risk of death.
The guideline states that surgery may be the starting treatment in patients whose general condition is very good, who have no accompanying comorbidities, and in whom the gynecologic oncologist believes optimal tumor-reducing surgery may be possible after comprehensive staging investigations.
Follow-up and treatment of ovarian cancer must be performed by teams including a gynecologic oncologist and a medical oncologist. It should not be forgotten that the most important factor determining success in all cancer types is offering the patient all scientifically proven treatment strategies in full. This development in ovarian cancer reminds us of an expression used in chess: “the most important move is the first move.”
Sources
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer.
Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. JCO October 2, 2016.
2. Vergote I et all.
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
N Engl J Med. 2010;363(10):943.
3. Kehoe S et all.
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.
Lancet. 2015;386(9990):249.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.